Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 6/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28523674 | 0.88 | GAA (0.44) | GAANFKB1NFKB2RELAHTR1A | |
| SCHEMBL4760840 | 0.86 | GAA (0.45) | GAANFKB1NFKB2RELAHTR1A | |
| SCHEMBL14001130 | 0.85 | HTR1A (0.36) | GAAHTR1AALDH1A1 | |
| SCHEMBL9906480 | 0.81 | GAA (0.50) | GAANFKB1NFKB2RELAALDH1A1 | |
| SCHEMBL7418257 | 0.80 | PYGL (0.52) | — | |
| SCHEMBL29048164 | 0.78 | SMN1; SMN2 (0.57) | GAAALDH1A1 | |
| SCHEMBL29048158 | 0.78 | ALDH1A1 (0.45) | GAAALDH1A1 | |
| SCHEMBL4760868 | 0.77 | GAA (0.45) | GAANFKB1NFKB2RELAF2 | |
| SCHEMBL21384512 | 0.77 | GAA (0.36) | GAANFKB1NFKB2RELAHTR1A | |
| SCHEMBL29048169 | 0.77 | HTR1A (0.50) | HTR1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198276-B2 | Kinase inhibitor compounds | XCOVERY HOLDING COMPANY LLC (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100144768-A1 | KINASE INHIBITOR COMPOUNDS | COMPASS HORIZON FUNDING COMPANY LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144768-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K9, MAP3K1, MAP3K8 | GAA 1840/4885NFKB1 663/4885NFKB2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.